Dr. Mikhail Blagosklonny is a top research scientist and respected oncologist. He currently works as an associate professor at the esteemed Roswell Park Cancer Institute. Aside from cancer research, Dr. Blagosklonny has studies and concentrates on developing anti-aging medicine. He is a renowned scholar and a proud alma matter of distinguished First Pavlov State Medical University of St. Petersburg where he obtained his M.D in medicine and doctorate in the areas of experimental medicine and cardiology.
Dr. Mikhail Blagosklonny’s work history and achievements
Dr. Mikhail Blagosklonny’s research projects at Roswell Park Cancer Institute revolve around clinical investigations, molecular and cellular biology with emphasis on cellular senescence, signal transduction, and anticancer therapeutics. Dr. Blagosklonny knowledge and expertise in the field of oncology speaks for itself. He joined the New York Medical College in 2002. Dr. Blagosklonny later acquired a job at Ordway Research Institute as a senior scientist. For years, he has developed an interest in designing effective cancer therapies. His interest is to develop drug therapies that destroy cancer cells and protect the healthy ones. Dr. Blagosklonny is also actively involved in mechanisms of aging and anti-aging drugs. He recently formulated a postulate on the use of TOR signaling in cancer and aging. Dr. Blagosklonny proposed the use of rapamycin, a drug used to suppress tumors, to extend the life expectancy of healthy individuals. He is one of the scientists who have conducted extensive research on this drug and, therefore, he understands its potential of prolonging life. Read more on Impact Journals.
Dr. Mikhail Blagosklonny’s editorial works
Dr. Blagosklonny has edited and published over 200 research papers, chapters medical books, reviews, and articles. He is the founder of Oncotarget, an informative open-access journal that publishes articles on a weekly basis. Dr. Blagosklonny together with his colleague Andrei Gudkov serve as the chief editors of this journal. Research papers posted on Oncotarget are those about oncology, aging, cell biology, endocrinology, and biotechnology. Under his management, Oncotarget has managed to become one of the top oncology journals globally. Dr. Blagosklonny also serves a senior editor of another leading medical journal dubbed Cell Cycle and Cancer Biology & Therapy journals. Additionally, Blagosklonny is a long-serving member of the editorial board of the Cell Death & Differentiation Journal, International Journal of Cancer, Autophagy, and PLOS ONE. View Mikhail’s profile on Google Scholar